5-MBPB

5-MBPB
Clinical data
ATC code
  • none
Legal status
Legal status
Identifiers
  • 1-(1-benzofuran-5-yl)-N-methylbutan-2-amine
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H17NO
Molar mass203.28 g/mol (freebase) 239.78 g/mol (hydrochloride) g·mol−1
3D model (JSmol)
  • CCC(CC1=CC2=C(OC=C2)C=C1)NC
  • InChI=1S/C13H17NO/c1-3-12(14-2)9-10-4-5-13-11(8-10)6-7-15-13/h4-8,12,14H,3,9H2,1-2H3
  • Key:CTEZPBCLIKEASW-UHFFFAOYSA-N

5-MBPB (also known as 5-MPBP and 5-MABB) is an amphetamine and phenylisobutylamine derivative which is structurally related to MDMA and has been sold as a designer drug. It can be described as the benzofuran-5-yl analogue of MBDB or the butanamine homologue of 5-MAPB, and is also a structural isomer of 5-EAPB and 6-EAPB. Anecdotal reports suggest this compound has been sold as a designer drug in various European countries since early 2015, but the first definitive identification was made in December 2015 by a forensic laboratory in Slovenia.[1]

5-MBPB is similar in structure to compounds such as 5-APB which are claimed to be agonists of the 5-HT2C receptor.[2]

5-MBPB (5-MABB) has been found to act as a potent serotonin–norepinephrine–dopamine releasing agent, with preference for induction of serotonin release over norepinephrine and dopamine release, and fully substitutes for MDMA in animal drug discrimination tests.[3]

References

  1. ^ European Monitoring Center for Drugs and Drug Addiction – Europol 2015 Annual Report on the implementation of Council Decision 2005/387/JHA
  2. ^ US patent 7045545, Karin Briner et al, "Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists", published 2000-01-19, issued 2006-16-03 
  3. ^ Johnson CB, Walther D, Baggott MJ, Baker LE, Baumann MH (September 2024). "Novel Benzofuran Derivatives Induce Monoamine Release and Substitute for the Discriminative Stimulus Effects of 3,4-Methylenedioxymethamphetamine". J Pharmacol Exp Ther. 391 (1): 22–29. doi:10.1124/jpet.123.001837. PMC 11413916. PMID 38272669.